Perspective Therapeutics
CATX
48 hedge funds and large institutions have $4.26M invested in Perspective Therapeutics in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 2 closing their positions.
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
37% more funds holding
Funds holding: 35 → 48 (+13)
15% more capital invested
Capital invested by funds: $3.7M → $4.26M (+$559K)
0.08% more ownership
Funds ownership: 1.13% → 1.21% (+0.08%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$378K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$92.2K |
| 3 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$28K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$27.5K |
| 5 |
VF
Virtu Financial
New York
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
-$154K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$25.7K |
| 3 |
WWA
WCG Wealth Advisors
Las Vegas,
Nevada
|
-$8K |
| 4 |
Millennium Management
New York
|
-$2.72K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$329 |
CATX Hedge Fund Activity: Q4 2022 in Review
48 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q4 2022, worth a combined $4.26M — up 15% from $3.7M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CATX positions and 2 closed out — a net gain of 13 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was HighTower Advisors, opening a new position worth an estimated $378K. The largest seller was Bard Associates, exiting entirely with an estimated $154K sold.
- 48 institutional investors held Perspective Therapeutics (CATX) as of Q4 2022, up from 35 in Q3 2022.
- Funds reported $4.26M of Perspective Therapeutics stock for Q4 2022, up 15% quarter-over-quarter.
- 15 funds opened new Perspective Therapeutics positions in Q4 2022 and 2 closed out, a net change of +13 holders.
- The largest Perspective Therapeutics buyer in Q4 2022 was HighTower Advisors, an estimated $378K added.
- The largest Perspective Therapeutics seller in Q4 2022 was Bard Associates, an estimated $154K sold.
Based on aggregated 13F filings for Q4 2022.